Wegovy: A Comprehensive Review

Obesity is a growing global health concern, and with it, the demand for effective weight management strategies has increased significantly.

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that has emerged as a promising treatment option for chronic weight management.

This comprehensive review will explore Wegovy’s mechanisms of action, efficacy, potential side effects, cost and insurance coverage, patient and doctor perspectives, and alternative medications.

How Wegovy Works

Wegovy’s effectiveness stems from its ability to mimic the action of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone in the body[1]. GLP-1 is released in the gut after eating and plays a crucial role in regulating appetite and food intake.

It acts on both the stomach and the brain1. In the stomach, GLP-1 slows down the rate of digestion, leading to a prolonged feeling of fullness.

In the brain, GLP-1 enhances satiety, which reduces appetite, food intake, and feelings of hunger.

By mimicking the effects of GLP-1, Wegovy helps individuals achieve weight loss by reducing appetite and promoting a sense of fullness[2].

Official Website of Wegovy

Several websites provide information about Wegovy, including those of regulatory agencies, healthcare providers, and the manufacturer.

The European Medicines Agency (EMA) website offers detailed information about Wegovy, including its approved uses, dosage, and potential side effects[2]. The EMA website also provides access to product information in various languages.

Novo Nordisk, the manufacturer of Wegovy, provides resources for healthcare professionals and patients on its NovoCare website. This website includes information about Wegovy’s mechanism of action, potential benefits, and support programs[3].

WeightWatchers, a weight management program, offers information about Wegovy on its website, including how to access the medication through their program[4].

The official Wegovy website provides comprehensive information about the medication, including its use, benefits, and potential side effects. The website also features a savings offer and personalized support program called WeGoTogether[5].

NovoMedLink, another website by Novo Nordisk, provides detailed medical information about Wegovy for healthcare professionals. This website includes information about Wegovy’s efficacy, safety, and prescribing information[6].

Effectiveness of Wegovy

Numerous clinical trials have demonstrated the efficacy of Wegovy in promoting weight loss and reducing the risk of cardiovascular events.

In a study involving adults with obesity or overweight and at least one weight-related health problem, individuals treated with Wegovy achieved an average weight loss of 15% after 68 weeks, compared to a 2% weight loss in the placebo group[2].

Notably, 84% of participants in the Wegovy group lost at least 5% of their body weight, compared to 31% in the placebo group. Another study involving adults without diabetes showed that those who received Wegovy lost an average of 12.4% of their initial body weight, while those who received a placebo experienced minimal weight loss[7].

Furthermore, Wegovy has been shown to be effective in adolescents with obesity[2].

A study involving adolescents aged 12 to less than 18 years with obesity demonstrated that after 68 weeks, BMI dropped by an average of 16% in those treated with Wegovy, compared to an average increase of less than 1% in those who received a placebo.

Approximately 73% of those who received Wegovy lost at least 5% of their weight, compared to around 18% of those who received a placebo.

In a significant development, the FDA approved Wegovy in 2024 to reduce the risk of major adverse cardiovascular events (MACE), such as cardiovascular death, heart attack, and stroke, in adults with cardiovascular disease and either obesity or overweight[8].

This approval was based on the results of a large-scale clinical trial involving over 17,600 participants, which showed that Wegovy significantly reduced the risk of MACE. Participants who received Wegovy had a 6.5% incidence of MACE, compared to 8% in the placebo group.

Importantly, research suggests that the weight loss benefits of Wegovy can be sustained for up to four years[9]. This finding is particularly noteworthy, as weight regain is a common challenge for individuals who discontinue other weight loss medications9.

Potential Side Effects of Wegovy

While Wegovy offers significant potential for weight management, it is essential to be aware of its potential side effects. The most commonly reported side effects are gastrointestinal in nature.

Gastrointestinal Side Effects:

• Nausea [10]
• Diarrhea [10]
• Vomiting [10]
• Constipation [10]
• Stomach pain [11]
• Bloating [11]
• Gas [11]
• Upset stomach [11]
• Heartburn [11]

Other Common Side Effects:

• Headache [11]
• Fatigue [11]
• Dizziness [11]

Serious Side Effects:

In addition to the common side effects, Wegovy may cause more serious adverse events, including:

• Inflammation of the pancreas (pancreatitis) [11]
• Gallbladder problems [11]
• Kidney problems [11]
• Increased heart rate [11]
• Changes in mood and behavior, including worsening depression and suicidal thoughts [12]

It is crucial for individuals considering Wegovy to discuss these potential side effects with their healthcare provider to make an informed decision about treatment.

Cost and Insurance Coverage of Wegovy

The cost of Wegovy can be a significant factor for many individuals.

The list price for a 28-day supply of Wegovy is about $1,350[13]. However, the actual out-of-pocket cost can vary depending on insurance coverage and the availability of savings programs[14].

Insurance coverage for Wegovy varies widely among different plans[15].

Some insurance plans may cover Wegovy with a copay, while others may not cover it at all. It is important to note that many insurance plans that do cover Wegovy have specific eligibility criteria that patients must meet.

These criteria may include having a certain BMI or weight-related health conditions.

Novo Nordisk offers a savings program called WeGoTogether to help patients with the cost of Wegovy[14].

This program can reduce the cost of Wegovy to as little as $0 for individuals with private or commercial insurance with prescription drug coverage.

For those without insurance coverage for Wegovy, the program offers a 28-day supply for $650[14].

In addition to the WeGoTogether program, there may be other options for reducing the cost of Wegovy, such as using a prescription discount card or exploring cheaper alternatives like compounded semaglutide.

Patient and Doctor Reviews of Wegovy

Patient reviews of Wegovy generally indicate a high level of satisfaction with the medication’s effectiveness in promoting weight loss[16].

Many patients report significant weight reduction, often accompanied by improvements in overall health and well-being.

Some patients have experienced side effects, such as nausea and vomiting, but these are typically mild and tend to subside over time[17].

Doctors also generally view Wegovy as an effective tool for weight management[18]. They acknowledge its potential to help patients achieve clinically significant weight loss and improve their health outcomes.

However, doctors emphasize that Wegovy is not a quick fix for obesity and should be used in conjunction with lifestyle modifications, such as a healthy diet and regular exercise[15].

Alternatives to Wegovy

While Wegovy has shown promising results, several alternative weight loss medications are available. These alternatives may be considered in cases where Wegovy is not suitable or not accessible.

Medication	Type	Mechanism of Action	Potential Benefits	Potential Side Effects
Wegovy (semaglutide)	GLP-1 receptor agonist	Mimics GLP-1 to reduce appetite and increase feelings of fullness	Significant weight loss, reduced risk of cardiovascular events	Nausea, diarrhea, vomiting, constipation
Saxenda (liraglutide)	GLP-1 receptor agonist	Mimics GLP-1 to reduce appetite and increase feelings of fullness	Weight loss	Nausea, diarrhea, vomiting, constipation
Zepbound (tirzepatide)	Dual GLP-1/GIP receptor agonist	Activates GLP-1 and GIP receptors to reduce appetite and increase feelings of fullness	Significant weight loss, potentially more effective than Wegovy	Nausea, vomiting, diarrhea, constipation
Ozempic (semaglutide)	GLP-1 receptor agonist	Mimics GLP-1 to reduce appetite and increase feelings of fullness	Weight loss, lower doses than Wegovy	Nausea, vomiting, diarrhea, constipation
Mounjaro (tirzepatide)	Dual GLP-1/GIP receptor agonist	Activates GLP-1 and GIP receptors to reduce appetite and increase feelings of fullness	Significant weight loss	Nausea, vomiting, diarrhea, constipation
Qsymia (phentermine/topiramate)	Combination medication	Affects neurotransmitters in the brain to reduce appetite and increase feelings of fullness	Weight loss	Dizziness, altered taste, insomnia, constipation, dry mouth
Contrave (naltrexone/bupropion)	Combination medication	Affects opioid receptors and dopamine pathways in the brain to reduce appetite and cravings	Weight loss	Nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, diarrhea

It is important to note that Zepbound, with its dual-agonist mechanism, may be more effective than Wegovy in promoting weight loss[19]. This is because it activates both GLP-1 and GIP receptors, leading to a more pronounced effect on appetite regulation.

Conclusion

Wegovy represents a significant advancement in the treatment of obesity and overweight. Its efficacy in promoting weight loss and reducing the risk of cardiovascular events has been well-established in clinical trials.

While potential side effects should be considered, they are generally manageable. The cost of Wegovy can be a barrier for some individuals, but savings programs and alternative medications may be available.

The long-term effects of Wegovy are still under investigation, and continued research is needed to fully understand its potential benefits and risks.

Further studies are also needed to evaluate the efficacy and safety of Wegovy in different patient populations, such as adolescents and individuals with specific medical conditions.

The use of weight loss medications like Wegovy raises ethical considerations that warrant careful attention. It is crucial to ensure that these medications are used responsibly and appropriately, and that patients are provided with comprehensive information about their benefits, risks, and potential long-term effects.

As the prevalence of obesity continues to rise, Wegovy and other weight loss medications may play an increasingly important role in addressing this global health challenge.

However, it is essential to remember that these medications are not a substitute for healthy lifestyle habits.

A comprehensive weight management strategy should include a balanced diet, regular exercise, and ongoing support from healthcare professionals.

What is Zepbound? Does this new weight loss drug work better than Wegovy and Ozempic? Will it cut costs? – UCHealth, accessed February 7, 2025, https://www.uchealth.org/today/zepbound-weight-loss-drug-compared-to-mounjaro-wegovy-ozempic/